

Cancer Causing Bacteria: A Review on Colorectal Cancer

Shrinu G. Ambade, Pratik B. Mandlik, Sanket A. Bhaik

Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra, India

Abstract: An increasing number of cancer cases have been reported throughout the years. Many cancers are linked to an unhealthy lifestyle and heredity. However, many do not know, infections caused by germs such as bacteria, viruses, fungi and sometimes parasites, can also lead to the development of cancer. In this review, we discuss the links between types of bacteria and cancer. Many viruses associated with human cancer are classified as human carcinogens by the International Agency for Research on Cancer, IARC. The cancer-causing germs described are *Helicobacter pylori* (stomach cancer), Epstein-Barr virus (stomach cancer and lymphoma), Hepatitis B and C (liver cancer), *Aspergillus spp.* (liver cancer), *Opisthorchis viverrine* (bile duct cancer), *Clonorchis sinensis* (bile duct cancer), *Fusobacterium nucleatum* (colorectal cancer), *Schistosoma haematobium* (bladder cancer); Human Papillomavirus (cervical cancer), and Kaposi's Sarcoma Herpes Virus (Kaposi's sarcoma). We will also discuss the cancer of the colorectal *Fusobacterium Nucleatum*.^[1]

Keywords: Cancer, Bacteria, Carcinogens, Parasites

REFERENCES

- [1]. Muhammad Nur Adam Hatta, Ezanee Azlina Mohamad Hanif, Siok-Fong Chin and Hui-min Neoh*, Pathogens and Carcinogenesis: A Review, Hatta, M.N.A.; Mohamad Hanif, E.A.; Chin, S.-F.; Neoh, H.-m. Pathogens and Carcinogenesis: A Review. Biology 2021, 10, 533. <https://doi.org/10.3390/biology10060533>.
- [2]. The American Cancer Society medical and editorial content team, cancer.org | 1.800.227.2345.
- [3]. Suad A Al-Hilu¹ and Wisam H Al-Shujairi², Review Article Dual Role of Bacteria in Carcinoma: Stimulation and Inhibition, Correspondence should be addressed to Suad A Al-Hilu; suaad.alhilo@uokufa.edu.iq Received 27 January 2020; Revised 10 July 2020; Accepted 30 July 2020; Published 24 August 2020 Academic Editor: Todd R. Callaway.
- [4]. Camilla Urbaniak,^{a,b} Joanne Cummins,^c Muriel Brackstone,^d Jean M. Macklaim,^{a,e} Gregory B. Gloor,^e Chwanrow K. Baban,^c Leslie Scott,^d Deidre M. O'Hanlon,^f Jeremy P. Burton,^a Kevin P. Francis,^g Mark Tangney,^c Gregor Reid,^{a,b} Microbiota of Human Breast Tissue, Received 21 January 2014 Accepted 27 February 2014 Published ahead of print 7 March 2014 Editor: G. T. Macfarlane Address correspondence to Gregor Reid, gregor@uwo.ca. C.U. and J.C. are joint first authors. M.T. and G.R. are joint senior authors. Supplemental material for this article may be found at
- [5]. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249.
- [6]. Chakraborty, S.; Rahman, T. The Difficulties in Cancer Treatment. Ecancermedicallscience 2012, 6, ed16.
- [7]. Pannone, G.; Zamparese, R.; Pace, M.; Pedicillo, M.C.; Cagiano, S.; Somma, P.; Errico, M.E.; Donofrio, V.; Franco, R.; De Chiara, A.; et al. The role of EBV in the pathogenesis of Burkitt's Lymphoma: An Italian hospital based survey. Infect. Agents Cancer 2014, 9, 1–11.
- [8]. Buckland, G.; Travier, N.; Huerta, J.; Bueno-De-Mesquita, H.; Siersema, P.; Skeie, G.; Weiderpass, E.; Engeset, D.; Ericson, U.; Ohlsson, B.; et al. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int. J. Cancer 2014, 137, 598–606.
- [9]. Graham, D.Y.; Miftahussurur, M. *Helicobacter pylori* urease for diagnosis of *Helicobacter pylori* infection: A mini review. J. Adv. Res. 2018, 13, 51–57.
- [10]. Shinozaki-Ushiku, A.; Kunita, A.; Aya, S.-U. Update on Epstein-Barr virus and gastric cancer (Review). Int.

- J. Oncol. 2015, 46, 1421–1434.
- [11]. Chuang, S.-C.; Vecchia, C.L.; Boffetta, P. Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. *Cancer Lett.* 2009, 286, 9–14.
 - [12]. McGivern, D.R.; Lemon, S.M. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. *Oncogene* 2011, 30, 1969–1983.
 - [13]. Sripa, B.; Brindley, P.J.; Mulvenna, J.; Laha, T.; Smout, M.; Mairiang, E.; Bethony, J.M.; Loukas, A. The tumorigenic liver fluke *Opisthorchis viverrini*—Multiple pathways to cancer. *Trends Parasitol.* 2012, 28, 395–407.
 - [14]. Shang, F.-M.; Liu, H.-L. *Fusobacterium nucleatum* and colorectal cancer: A review. *World J. Gastrointest. Oncol.* 2018, 10, 71–81.
 - [15]. Ma, C.; Luo, H.; Gao, F.; Tang, Q.; Chen, W. *Fusobacterium nucleatum* promotes the progression of colorectal cancer by interacting with E-cadherin. *Oncol. Lett.* 2018, 16, 2606–2612.
 - [16]. Doorbar, J.; Quint, W.; Banks, L.; Bravo, I.G.; Stoler, M.; Broker, T.R.; Stanley, M.A. The Biology and Life-Cycle of Human Papillomaviruses. *Vaccine* 2012, 30, F55–F70.
 - [17]. M. Castellarin, R. L. Warren, J. D. Freeman et al., “*Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma,” *Genome Research*, vol. 22, no. 2, pp. 299–306, 2012.
 - [18]. M. J. Hill, “Chronic bacterial infection and subsequent human carcinogenesis,” *European Journal of Cancer Prevention: Official Journal of the European Cancer Prevention Organisation (ECP)*, vol. 4, no. 2, pp. 127–128, 1995.
 - [19]. F.-M. Shang and H.-L. Liu, “*Fusobacterium nucleatum* and colorectal cancer: a review,” *World Journal of Gastrointestinal Oncology*, vol. 10, no. 3, pp. 71–81, 2018.
 - [20]. S. A. d. Reis, L. L. da Conceição, and M. d. C. G. Peluzio, “Intestinal microbiota and colorectal cancer: changes in the intestinal microenvironment and their relation to the disease,” *Journal of Medical Microbiology*, no. 10, pp. 1391–1407, 2019.
 - [21]. Aslowski, M. Takahashi, Y. Nakanishi et al., “Attenuated *Salmonella typhimurium* cancer therapy has direct effects on the tumor epithelium in colorectal cancer,” *Biorxiv*, Article ID 741686, 2019.
 - [22]. I. Koliarakis, I. Messaritakis, T. K. Nikolouzakos, G. Hamilos, J. Souglakos, and J. Tsiaoussis, “Oral bacteria and intestinal dysbiosis in colorectal cancer,” *International Journal of Molecular Sciences*, vol. 20, no. 17, p. 4146, 2019.
 - [23]. J. Yu, Q. Feng, S. H. Wong et al., “Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer,” *Gut*, vol. 66, no. 1, pp. 70–78, 2017.
 - [24]. K. Nosh, “Association of *Fusobacterium nucleatum* with immunity and molecular alterations in colorectal cancer,” *World Journal of Gastroenterology*, vol. 22, no. 2, pp. 557–566, 2016.
 - [25]. Y. Yang, B. B. Misra, L. Liang et al., “Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer,” *eranostics*, vol. 9, no. 14, pp. 4101–4114, 2019.
 - [26]. P. Gholizadeh, H. Eslami, and H. S. Kafil, “Carcinogenesis mechanisms of *Fusobacterium nucleatum*,” *Biomedicine & Pharmacotherapy*, vol. 89, pp. 918–925, 2017.
 - [27]. E. Nistal, N. Fernandez-Fernández, S. Vivas, and J. L. Olcoz, “Factors determining colorectal cancer: the role of the intestinal microbiota,” *Frontiers in Oncology*, vol. 5, no. 220, 2015.
 - [28]. Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Clinical utility of circulating tumor DNA for colorectal cancer. *Cancer Sci.* 2019;110(4):11481155.